{
    "id": 27616,
    "fullName": "EGFR V765_M766delinsHH",
    "impact": "indel",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "EGFR V765_M766delinsHH results in a deletion of two amino acids in the protein kinase domain of the Egfr protein from aa 745 to aa 746, combined with the insertion of two histidines (H) at the same site (UniProt.org). V765_M766delinsHH has been demonstrated to confer resistance to some Egfr inhibitors in culture (PMID: 29467275), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 11222,
                    "pubMedId": 29467275,
                    "title": "Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29467275"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "V765_M766delinsHH",
    "createDate": "04/16/2018",
    "updateDate": "10/06/2019",
    "referenceTranscriptCoordinates": {
        "id": 135956,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55181302_55181307delinsCATCAT",
        "cDna": "c.2293_2298delinsCATCAT",
        "protein": "p.V765_M766delinsHH",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 13640,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both EGFR L858R and EGFR V765_M766delinsHH were resistant to Gilotrif (afatinib) in culture (PMID: 29467275).",
            "molecularProfile": {
                "id": 29168,
                "profileName": "EGFR V765_M766delinsHH EGFR L858R"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11222,
                    "pubMedId": 29467275,
                    "title": "Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29467275"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13639,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both EGFR L858R and EGFR V765_M766delinsHH were resistant to Tarceva (erlotinib) in culture (PMID: 29467275).",
            "molecularProfile": {
                "id": 29168,
                "profileName": "EGFR V765_M766delinsHH EGFR L858R"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11222,
                    "pubMedId": 29467275,
                    "title": "Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29467275"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 29167,
            "profileName": "EGFR V765_M766delinsHH",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29168,
            "profileName": "EGFR V765_M766delinsHH EGFR L858R",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 135956,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55181302_55181307delinsCATCAT",
            "cDna": "c.2293_2298delinsCATCAT",
            "protein": "p.V765_M766delinsHH",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}